Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 11/2016

01-11-2016 | Original Article

IFITM3 and severe influenza virus infection. No evidence of genetic association

Authors: M. López-Rodríguez, E. Herrera-Ramos, J. Solé-Violán, J. J. Ruíz-Hernández, L. Borderías, J. P. Horcajada, E. Lerma-Chippirraz, O. Rajas, M. Briones, M. C. Pérez-González, M. A. García-Bello, E. López-Granados, F. Rodriguez de Castro, C. Rodríguez-Gallego

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2016

Login to get access

Abstract

Influenza virus infection (IVI) is typically subclinical or causes a self-limiting upper respiratory disease. However, in a small subset of patients IVI rapidly progresses to primary viral pneumonia (PVP) with respiratory failure; a minority of patients require intensive care unit admission. Inherited and acquired variability in host immune responses may influence susceptibility and outcome of IVI. However, the molecular basis of such human factors remains largely elusive. It has been proposed that homozygosity for IFITM3 rs12252-C is associated with a population-attributable risk of 5.4 % for severe IVI in Northern Europeans and 54.3 % for severe H1N1pdm infection in Chinese. A total of 148 patients with confirmed IVI were considered for recruitment; 118 Spanish patients (60 of them hospitalized with PVP) and 246 healthy Spanish individuals were finally included in the statistical analysis. PCR-RFLP was used with confirmation by Sanger sequencing. The allele frequency for rs12252-C was found to be 3.5 % among the general Spanish population. We found no rs12252-C homozygous individuals in our control group. The only Spanish patient homozygous for rs12252-C had a neurological disorder (a known risk factor for severe IVI) and mild influenza. Our data do not suggest a role of rs12252-C in the development of severe IVI in our population. These data may be relevant to recognize whether patients homozygous for rs12252-C are at risk of severe influenza, and hence require individualized measures in the case of IVI.
Literature
1.
3.
go back to reference Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179–186CrossRefPubMed Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179–186CrossRefPubMed
4.
go back to reference Hayward AC, Fragaszy EB, Bermingham A, Wang L, Copas A, Edmunds WJ et al (2014) Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med 2(6):445–454. doi:10.1016/S2213-2600(14)70034-7 CrossRefPubMed Hayward AC, Fragaszy EB, Bermingham A, Wang L, Copas A, Edmunds WJ et al (2014) Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med 2(6):445–454. doi:10.​1016/​S2213-2600(14)70034-7 CrossRefPubMed
5.
go back to reference Albright FS, Orlando P, Pavia AT, Jackson GG, Cannon Albright LA (2008) Evidence for a heritable predisposition to death due to influenza. J Infect Dis 197:18–24. doi:10.1086/524064 CrossRefPubMed Albright FS, Orlando P, Pavia AT, Jackson GG, Cannon Albright LA (2008) Evidence for a heritable predisposition to death due to influenza. J Infect Dis 197:18–24. doi:10.​1086/​524064 CrossRefPubMed
6.
go back to reference Horby P, Nguyen NY, Dunstan SJ, Baillie JK (2013) An updated systematic review of the role of host genetics in susceptibility to influenza. Influenza Other Respir Viruses (Suppl 2):37–41. doi:10.1111/irv.12079 Horby P, Nguyen NY, Dunstan SJ, Baillie JK (2013) An updated systematic review of the role of host genetics in susceptibility to influenza. Influenza Other Respir Viruses (Suppl 2):37–41. doi:10.​1111/​irv.​12079
7.
go back to reference Keynan Y, Malik S, Fowke KR (2013) The role of polymorphisms in host immune genes in determining the severity of respiratory illness caused by pandemic H1N1 influenza. Public Health Genomics 16(1–2):9–16. doi:10.1159/000345937 CrossRefPubMed Keynan Y, Malik S, Fowke KR (2013) The role of polymorphisms in host immune genes in determining the severity of respiratory illness caused by pandemic H1N1 influenza. Public Health Genomics 16(1–2):9–16. doi:10.​1159/​000345937 CrossRefPubMed
8.
go back to reference Herrera-Ramos E, López-Rodríguez M, Ruíz-Hernández JJ, Horcajada JP, Borderías L, Lerma E et al (2014) Surfactant protein A genetic variants associate with severe respiratory insufficiency in pandemic influenza A virus infection. Crit Care 18(3):R127. doi:10.1186/cc13934 CrossRefPubMedPubMedCentral Herrera-Ramos E, López-Rodríguez M, Ruíz-Hernández JJ, Horcajada JP, Borderías L, Lerma E et al (2014) Surfactant protein A genetic variants associate with severe respiratory insufficiency in pandemic influenza A virus infection. Crit Care 18(3):R127. doi:10.​1186/​cc13934 CrossRefPubMedPubMedCentral
13.
go back to reference Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X et al (2014) Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci USA 111(2):769–774. doi:10.1073/pnas.1321748111 CrossRefPubMed Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X et al (2014) Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci USA 111(2):769–774. doi:10.​1073/​pnas.​1321748111 CrossRefPubMed
14.
Metadata
Title
IFITM3 and severe influenza virus infection. No evidence of genetic association
Authors
M. López-Rodríguez
E. Herrera-Ramos
J. Solé-Violán
J. J. Ruíz-Hernández
L. Borderías
J. P. Horcajada
E. Lerma-Chippirraz
O. Rajas
M. Briones
M. C. Pérez-González
M. A. García-Bello
E. López-Granados
F. Rodriguez de Castro
C. Rodríguez-Gallego
Publication date
01-11-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2016
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2732-7

Other articles of this Issue 11/2016

European Journal of Clinical Microbiology & Infectious Diseases 11/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine